STAT Plus: FDA refuses application for HIV drug from CytoDyn, raising more questions about its credibility
The Food and Drug Administration refused to accept an application seeking the approval of a…
Category: STAT Plus
STAT Plus: Telemedicine is more convenient during Covid-19. It’s also a magnet for fraud and data theft
The increased convenience of telemedicine visits during the Covid-19 pandemic is spurring calls among patients…
STAT Plus: How can cancer drug prices better match their benefits? Germany offers a cost-saving model
A new study finds that after Germany revamped its approach to purchasing medicines a decade…
STAT Plus: As European Commission decision looms, Google faces continued scrutiny over Fitbit deal
Google is again facing questions from regulators about its $2.1 billion bid for Fitbit. The…
STAT Plus: Pharmalittle: BioNTech expects to seek approval for vaccine by year-end; why the FDA chose a 50% threshold for Covid-19 vaccines
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Relay Therapeutics, focused on solid tumors, seeks to raise $250M in IPO
Relay Therapeutics, a Cambridge, Mass.-biotech focusing on cancer treatments, plans to raise $250 million when…
STAT Plus: A new tool aims to help patients sort through 200 mental health apps — and counting
There are nearly 20,000 mental health apps that will do everything from tracking a person’s…
Despite the pandemic, prices for many drugs keep rising
Despite the economic hardships the Covid-19 pandemic has created for many Americans, drug makers raised…
STAT Plus: How does exercise benefit the aging brain? Transfusing blood from active mice into sedentary ones suggests an answer
Exercise has been shown to slow cognitive decline in aging, but scientists haven’t known why….
STAT Plus: Two dozen big drug makers launch a $1 billion fund to develop new antibiotics
In response to heightened concerns over antibiotic resistance, two dozen of the world’s largest pharmaceutical…
STAT Plus: Pharmalittle: Gilead to boost remdesivir supplies in Europe; drug makers announcing $1 billion antibiotic innovation fund
Good morning, everyone, and welcome to another busy day. You made it this far this…
.jpg)
STAT Plus: AbbVie may face fewer wrinkles after judge suggests a 10-year ban on a Botox rival
In a boost for AbbVie (ABBV), a U.S. International Trade Commission judge this week made…
STAT Plus: A moment of truth arrives for CytoDyn’s Covid-19 drug. Don’t let spin obscure it
CytoDyn is nearing the completion of a clinical trial investigating the use of leronlimab, its…
STAT Plus: Pharmalittle: Will a coronavirus vaccine be budget-breaking? Europe has deals with Merck and Roche for Covid-19 drugs
Rise and shine, another busy day is on the way. We can tell because the…
STAT Plus: Proving predictions wrong, health tech funding keeps climbing
Despite forecasts that investments in health tech would dry up by mid-year, venture funding for…
STAT Plus: Did a pharma trade group try to sabotage a Dutch government report on compulsory licensing?
A Dutch government commission on compulsory licensing was nearly sabotaged last month after one of…
STAT Plus: With a clinical hold, off-the-shelf CAR-T hits a new safety concern
The Food and Drug Administration has placed a clinical hold on one of Cellectis’s off-the-shelf…
STAT Plus: Pharmalittle: U.S. scientists and Moderna squabble over Covid-19 vaccine; BARDA doles out big coronavirus contract
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT Plus: Lobbyists tied to President Trump represent more than a dozen companies working on Covid-19
More than a dozen companies developing Covid-19 vaccines, therapies or diagnostics — including several of…
STAT Plus: Venter Institute, Yumanity, and other biopharma companies among recipients of PPP loans
Yumanity, the J. Craig Venter Institute, and dozens of other companies around the biotech industry…
STAT Plus: Johnson & Johnson lowers the price of its TB drug in many poor countries, but is it enough?
After protracted criticism over its pricing for a game-changing tuberculosis medicine, Johnson & Johnson (JNJ)…
STAT Plus: Pharmalittle: Covid-19 trials are marked by disorganization; FDA approves a new type of HIV treatment
Good morning, everyone, and welcome to another working week. We hope the weekend respite, which…
STAT Plus: Immunomedics’ breast cancer drug delays tumor growth, prolongs survival in clinical trial
Immunomedics reported clinical trial results Monday showing its newly approved medicine, Trodelvy, reduced the risk…
STAT Plus: Bellus Health suffers setback with clinical trial failure of chronic cough drug
Bellus Health is reporting Monday negative results from a mid-stage clinical trial of its experimental…
STAT Plus: Alexion to pay $21 million for failing to record bribes paid to doctors in other countries
Alexion Pharmaceuticals (ALXN) agreed to pay more than $21 million for maintaining a false set…
STAT Plus: Pharmalittle: Trump officials maintain Covid-19 vaccine won’t be influenced by politics; Novartis pays $678 million to settle kickback charges
And so, another working week will soon come to an end. Not a moment too…
STAT Plus: Novartis pays $678 million to settle a long-running case over alleged kickbacks to doctors
After seven years of sparring, Novartis (NVS) has agreed to pay $678 million to settle…
STAT Plus: Africa Union urges member countries to remove intellectual property barriers to Covid-19 vaccines
Amid growing concern over access to Covid-19 medical products, the organization that represents dozens of…
Experimental HIV drug seems effective at a twice-a-year dose, study finds
An experimental new HIV treatment could, with just one dose, reduce the amount of virus…
STAT Plus: Drug makers sue to block Minnesota law making it cheaper to get insulin in emergencies
WASHINGTON — The drug industry lobbying association PhRMA sued the state of Minnesota over a…
STAT Plus: Pharmalittle: FDA sets Covid-19 vaccine guidance; White House grabs much of the remdesivir supply
Rise and shine, everyone, another busy day is on the way. Yes, indeed, the middle…
STAT Plus: Indivior CEO pleads guilty in connection with a scheme to promote Suboxone
The chief executive of Indivior pleaded guilty to misbranding Suboxone Film, a medicine used to…
STAT Plus: Canadian court upholds most of a controversial new rule for controlling excessive drug prices
In a setback to the pharmaceutical industry, a federal court judge in Canada has dismissed…
STAT Plus: After years of feuds, Vertex and the U.K. government reach a deal over cystic fibrosis medicines
U.K. officials and Vertex Pharmaceuticals (VRTX) have finally put to rest a years-long battle over…
STAT Plus: Pharmalittle: FDA to issue guidance on Covid-19 vaccines; what remesdivir pricing may really mean
Top of the morning to you, and a fine one it is. A shiny sun…
STAT Plus: The biotech scorecard for the third quarter: 14 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the third…
STAT Plus: Gilead’s pricing for remdesivir raises questions about the drug’s long-term prospects
After weeks of anticipation, Gilead Sciences (GILD) finally disclosed the pricing for its remdesivir experimental…
STAT Plus: How Gilead’s remdesivir price could come back to haunt the drug industry
Gilead Sciences, in a self-described effort to do “the right and responsible thing,” may have…
STAT Plus: Pharma trade group scolds AstraZeneca for bad behavior over an advisory board
A U.K. pharmaceutical industry trade group has publicly reprimanded AstraZeneca (AZN) for failing to uphold…
STAT Plus: Pharmalittle: Pharma giants plan $1 billion antibiotic venture; Gilead prices remdesivir below most estimates
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: FDA rejects Intercept Pharma’s drug for NASH
Intercept Pharmaceuticals said Monday that the Food and Drug Administration rejected its drug to treat…
STAT Plus: Pharma giants to unveil major $1 billion venture to push novel antibiotics
Amid escalating concerns over antibiotic resistance, several big drug makers are creating a new $1…
STAT Plus: Pfizer sues Trump administration over anti-kickback rules, saying they prevent it from helping lower seniors’ drug costs
WASHINGTON — Pharmaceutical giant Pfizer is suing the Trump administration over two long-standing Medicare rules…
STAT Plus: Pharmalittle: Sanofi to cut hundreds of jobs; former BARDA chief claims Azar is sabotaging his new job
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Zogenix wins approval for new drug to treat rare type of childhood epilepsy
A new drug from Zogenix that treats a rare and severe type of epilepsy was…
STAT Plus: Novartis to pay $345 million to U.S. authorities for bribing doctors in different countries
Novartis (NVS) agreed to pay more than $345 million to resolve criminal charges brought by…
STAT Plus: Pharmalittle: NIH may own patents for the Moderna Covid-19 vaccine; ICER boosts recommended price for remdesivir
Hello, everyone, and how are you this morning? Another balmy day is unfolding here on…
STAT Plus: A pill to fight alcoholism causes an uproar in France over a regulator’s view of a clinical trial
Two years ago, French regulators made a surprising decision, overruling one of their own expert…
STAT Plus: Federal prosecutors allege Regeneron used a charity to pay kickbacks to Medicare patients
Federal officials on Wednesday alleged that Regeneron Pharmaceuticals (REGN) donated tens of millions of dollars…
STAT Plus: Engineering a better immunotherapy to outwit cancer — and launch a biotech
Tweaking an immune cell called interleukin-18 can overcome tumors that lure it into binding with…